Aptazapine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Aptazapine
DrugBank Accession Number
DB09305
Background

Aptazapine (CGS-7525A) was a tetracyclic antidepressant developed in the 1980s. Aptazapine had noradrenergic and specific serotonergic activity. It antagonised α2 adrenergic receptors approximately 10 times more effectively than mianserin, antagonised 5-HT2 receptors, agonised H1 receptors, and did not affect reuptake of serotonin or norepinephrine. Although Aptazapine reached clinical trials, it was never marketed.

Type
Small Molecule
Groups
Experimental
Structure
Thumb
Weight
Average: 253.349
Monoisotopic: 253.157897624
Chemical Formula
C16H19N3
Synonyms
  • Aptazapine
External IDs
  • CGS 7525A
  • CGS-7525A

Pharmacology

Indication

Investigated for the treatment of depression.

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Aptazapine.
LevothyroxineThe risk or severity of adverse effects can be increased when Levothyroxine is combined with Aptazapine.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Aptazapine.
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Aptazapine.
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Aptazapine.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Aptazapine.
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Aptazapine.
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Aptazapine.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Aptazapine.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Aptazapine.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Product Ingredients
IngredientUNIICASInChI Key
Aptazapine maleate7X768418RT71576-41-5JJTOHZLQMBVMPF-BTJKTKAUSA-N

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzodiazepines
Sub Class
1,4-benzodiazepines
Direct Parent
1,4-benzodiazepines
Alternative Parents
Dialkylarylamines / N-methylpiperazines / Aralkylamines / Benzenoids / Pyrroles / Heteroaromatic compounds / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
1,4-benzodiazepine / 1,4-diazinane / Amine / Aralkylamine / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Dialkylarylamine / Heteroaromatic compound / Hydrocarbon derivative
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
240J927J1R
CAS number
71576-40-4
InChI Key
MNHDDERDSNZCCK-UHFFFAOYSA-N
InChI
InChI=1S/C16H19N3/c1-17-9-10-19-14-6-3-2-5-13(14)11-18-8-4-7-15(18)16(19)12-17/h2-8,16H,9-12H2,1H3
IUPAC Name
17-methyl-6,14,17-triazatetracyclo[12.4.0.0²,⁶.0⁸,¹³]octadeca-2,4,8(13),9,11-pentaene
SMILES
CN1CCN2C(C1)C1=CC=CN1CC1=C2C=CC=C1

References

General References
  1. Gower AJ, Broekkamp CL, Rijk HW, Van Delft AM: Pharmacological evaluation of in vivo tests for alpha 2-adrenoceptor blockade in the central nervous system and the effects of the enantiomers of mianserin and its aza-analog ORG 3770. Arch Int Pharmacodyn Ther. 1988 Jan-Feb;291:185-201. [Article]
  2. Liebman JM, Lovell RA, Braunwalder A, Stone G, Bernard P, Barbaz B, Welch J, Kim HS, Wasley JW, Robson RD: CGS 7525A, a new, centrally active alpha 2 adrenoceptor antagonist. Life Sci. 1983 Jan 24;32(4):355-63. [Article]
PubChem Compound
51355
PubChem Substance
310265194
ChemSpider
46513
ChEMBL
CHEMBL336712
Wikipedia
Aptazapine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.7 mg/mLALOGPS
logP2.48ALOGPS
logP2.69ChemAxon
logS-2ALOGPS
pKa (Strongest Basic)6.92ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area11.41 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity78.91 m3·mol-1ChemAxon
Polarizability29.05 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on November 12, 2015 16:14 / Updated on February 21, 2021 18:52